Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.

Autor: Álvarez-Díaz DA; Grupo de Genómica de Microorganismos Emergentes, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia., Laiton-Donato K; Grupo de Genómica de Microorganismos Emergentes, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia., Torres-García OA; Faculty of Veterinary Medicine and Zootechnics, Universidad Antonio Nariño, Bogotá, Colombia., Ruiz-Moreno HA; Grupo de Genómica de Microorganismos Emergentes, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia., Franco-Muñoz C; Grupo de Genómica de Microorganismos Emergentes, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia; Grupo de Parasitología, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia., Beltran MA; Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia., Mercado-Reyes M; Grupo de Genómica de Microorganismos Emergentes, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia., Rueda MG; Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia., Muñoz AL; Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia; Faculty of Science, Universidad Antonio Nariño, Calle 23 #116-31, Bodega 26, Bogotá, Colombia. Electronic address: ana.munoz@hemolfeamerica.org.
Jazyk: angličtina
Zdroj: Virus research [Virus Res] 2022 Jan 15; Vol. 308, pp. 198629. Date of Electronic Publication: 2021 Nov 12.
DOI: 10.1016/j.virusres.2021.198629
Abstrakt: The E484K mutation at the SARS-CoV-2 Spike protein emerged independently in different variants around the world and has been widely associated with immune escape from neutralizing antibodies generated during previous infection or vaccination. In this work, the B.1 + L249S+E484K lineage was isolated along with A.1, B.1.420, and B.1.111 SARS-CoV-2 lineages without the E484K mutation and the neutralizing titer of convalescent sera was compared using microneutralization assays. While no significant differences in the neutralizing antibody titers were found between A.1 and B.lineages without the E484K mutation, the neutralizing titers against B.1 + L249S+E484K were 1.5, 1.9, 2.1, and 1.3-fold lower than against A.1, B.1.420, B.1.111-I, and B.1.111-II, respectively. However, molecular epidemiological data indicate that there is no increase in the transmissibility rate associated with this new lineage. This study supports the capability of new variants with the E484K mutation to be resistant to neutralization by humoral immunity, and therefore the need to intensify surveillance programs to determine if these lineages represent a risk for public health.
(Copyright © 2021. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: